- Earth
Science Tech is looking to expand its line of work through two wholly
owned subsidiaries
- Its
subsidiaries focus on R&D and product development
- The
company recently outlined a five-year marketing and manufacturing plan
Earth Science Tech Inc. (OTCQB: ETST) is an aspiring
biotech company engaged in the development of cannabinoid-based products and
the research and development of medical devices and pharmaceuticals. Using the
supercritical CO2 liquid extraction, isolation and micron filtration process,
the company manufactures 100 percent natural CBD oil. This pure, easily
digested, rich CBD hemp oil is unique to the nutraceuticals industry and
represents a significant asset to ETST.
Earth Science Tech is currently looking to expand its
operations in the areas of CBD product development and R&D of medical
devices and pharmaceuticals through its two wholly owned subsidiaries: Earth
Science Pharma Inc. and Cannabis Therapeutics Inc.
Earth Science Pharma Inc. is focused on the research and
development of low-cost medical devices and vaccines that benefit women’s
health. The company recently introduced its first medical device, MSN-2, a home
kit designed for the detection of STIs such as chlamydia. The company has named
this kit Hygee. By circumventing the need for laboratory analysis, ETST
anticipates that the kit will empower women across the world, giving them a
low-cost, noninvasive method to meet their diagnostic health care needs (http://ibn.fm/HROu1).
Aside from Earth Science Pharma’s innovations in the
diagnostic health care space, ETST has another subsidiary operating in the
burgeoning cannabis industry. Cannabis Therapeutics Inc. is committed to the
research and development of medicinal cannabidiol. The company also possesses a
provisional application patent for a CBD product that can be used for
developing medications to treat breast and ovarian cancers.
ETST recently filed a 10-K annual report with the SEC that
included an outline of the company’s five-year expansion plan for manufacturing
and marketing its CBD products (http://ibn.fm/JY9mT). The plan includes information about
the company’s strategic preparations to scale up the production of its CBD oil,
introduce new products and make its innovative hemp products available
worldwide (http://ibn.fm/5OZ0R).
Earth Science Tech has teamed up with the University of
Central Oklahoma to conduct research and development projects. In addition,
studies from the DV Biologics Laboratory scientifically support and advance the
health care benefits of the company’s high-grade hemp CBD oil. These studies
show positive results regarding breast cancer and immune cells to support that
ETST’s CBD oil formulation lowers cortisol and functions as a neuro-protectant,
with positive-result case studies conducted through key health organizations.
“Our CBD-rich hemp oil does not contain any synthetic cannabinoids
and is not an isolate,” the SEC report noted. “It contains everything that is
naturally occurring in the original industrial hemp plant. With our
high-quality, CBD-rich hemp oil you benefit from the natural interaction of
phytonutrients in their balanced wide-ranging form that may offer the most
benefit for overall wellness.” The report further noted that the company’s
“commercialized, CBD-based product line, High-Grade Full Spectrum Cannabinoids,
offers seven distinct cannabinoids maximizing all the therapeutic benefits the
industrial hemp plant has to offer.”
Through the innovative products offered by its two wholly
owned subsidiaries, ETST is well-positioned to stay abreast of current trends
in multiple markets.
For more information, visit the company’s website at www.EarthScienceTech.com
NOTE TO INVESTORS: The latest news and updates
relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
